Institut fuer Klinische Krebsforschung IKF GmbH

• The CLEAN-DUCT / TRITICC-3 trial - Phase IIa, prospective, single arm, open label, non-randomized, multi-center pilot study of durvalumab (M… Recruiting
  2023-509165-21-00 Phase II 1 country DURVALUMAB
• Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A ra… Recruiting
  2023-504141-31-00 Phase II 1 country
• TRAP-BTC Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer Ended
  2023-505722-33-00 Phase II 1 country CISPLATIN; GEMCITABINE HYDROCHLORIDE; PEMBROLIZUMAB; TRASTUZUMAB
• IMMUWHY Ended
  2023-508314-42-00 Phase II 2 countries DURVALUMAB; TREMELIMUMAB
• The NeoTRACK Trial – Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – Dissection of IO efficacy in NSCLC by longitudinal tracKing: a… Halted
  2022-501322-38-00 Phase II 1 country TIRAGOLUMAB
• A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metast… Ended
  2023-505257-40-00 Phase I/II 2 countries
• RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Ended
  2023-505441-69-00 Phase III 4 countries NIVOLUMAB; REGORAFENIB

Showing 1–7 of 7 trials